Everything below concerns REV-ERB. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Pregnenolone acetate (brand names Antofin, Previsone, Pregno-Pan), also known as pregn-5-en-3β-ol-20-one 3β-acetate, is a synthetic pregnane steroid and an ester of pregnenolone which is described as a glucocorticoid and as a skin-conditioning and skin anti-aging agent. It has been reported to reduce wrinkles in elderly women when applied in the form of a 0.5% topical cream, effects which were suggested to be due to improved hydration of the skin. Pregnenolone acetate has been marketed in France in a topical cream containing 1% pregnenolone acetate and 10% "sex hormone" for the treatment of premature skin aging but was withdrawn from the market in 1992. Although the medication has been described by some sources as a glucocorticoid, other authors have stated that systemic pregnenolone acetate has no undesirable metabolic or toxic effects even at high doses.
Historic England. "Bawdsey Chain Home Station (1309533)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "Great Bromley Chain Home Station (1476819)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "Canewdon Chain Home Station (1412472)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "Dunkirk Chain Home Station (1377189)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "High Street Chain Home Station (1476863)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "Pevensey Chain Home Station (1476551)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "Rye Chain Home Station (1476520)". Research records (formerly PastScape). Retrieved 9 October 2015. Historic England. "Ventnor Chain Home Station (1306901)". Research records (formerly PastScape). Retrieved 9 October 2015. Early Radar Memories Archived 2 September 2010 at the Wayback Machine Memories of Sgt. Jean Semple, one of Britain's pioneer radar operators RAF Bawdsey Chain Home Radar Station at Subterranean Britain RAF Radar Museum RAF High Street picture Life at Darsham Deprecated link archived 19 April 2013 at archive.today – BBC Great Baddow Chain Home Mast & Radar Anniversary Chain Home Radar – A Personal Reminiscence, M Scanlan, GEC Review, 1993 Early radar development in the UK at purbeckradar.co.uk 60 (Signals) Group, Fighter Command Archived 16 November 2017 at the Wayback Machine (pdf)
The largest internationally operating media companies in Germany are Bertelsmann, Axel Springer SE and ProSiebenSat.1 Media. Germany's television market is the largest in Europe, with over 38 million TV households as of 2012. Around 90% of German households have cable or satellite TV, with a variety of free-to-view public and commercial channels. There are more than 300 public and private radio stations in Germany; Germany's national radio network is the Deutschlandradio, while the public Deutsche Welle is the main radio and television broadcaster in foreign languages. Germany's print media market is the largest in Europe. The German newspapers with the highest circulation are Bild, Süddeutsche Zeitung, Frankfurter Allgemeine Zeitung and Die Welt. The largest German magazines include ADAC Motorwelt and Der Spiegel. Germany has a large video gaming market, with over 34 million players nationwide. The annual Gamescom held in Cologne is the world's largest gaming convention. German cinema has made major technical and artistic contributions to film. The first works of the Skladanowsky Brothers were shown to an audience in 1895. The renowned Babelsberg Studio in Potsdam was established in 1912, thus being the first large-scale film studio in the world. Early German cinema was particularly influential with German expressionists such as Robert Wiene and Friedrich Wilhelm Murnau. Director Fritz Lang's Metropolis (1927) is referred to as the first major science-fiction film.
== Cell-cell communication == Migrating isolated cell responds to cues in its environment and changes its behavior accordingly. As cell-cell communication does not play a major role in this case, similar trajectories are observed in different isolated cells. However, when the cell migrates as part of the collective, it not only responds to its environment but also interacts with other cells through soluble substrates and physical contact. These cell-cell communication mechanisms are the main reasons for the difference between efficient migration of the collective and random walk movements of the isolated cell. Cell-cell communication mechanisms are widely studied experimentally (in vivo and in vitro), and computationally (in silico).
Rejuva is a gene therapy which is under development for the treatment of obesity and diabetes. It is an adeno-associated virus (AAV)-based gene therapy which involves an engineered variant of human insulin promotor and which aims to permanently increase nutrient-responsive secretion glucagon-like peptide-1 (GLP-1) by pancreatic β-cells. The therapy is administered via a 25-gauge needle delivery system guided by endoscopic ultrasound in a one-time outpatient treatment. It is intended as a permanent alternative to GLP-1 agonists like semaglutide. Rejuva is under development by Fractyl Health and is in the preclinical research stage of development.
Sources: en.wikipedia.org
=== Innovation and novel ideas === Kalra coined the term "barocrinology" to describe the endocrine science of obesity. He has since proposed numerous concepts related to "baro-health" and serves as a section editor in the barocrinology division of a major South Asian PubMed-indexed journal. His contributions include the Barocene Era, barometric nervosa, bariatric pyramid, baromania, baro-bullying, lipokathexis, the Ominous Octet of Obesity, and viewing obesity as a communicable disease—concepts intended to provide simplified frameworks for understanding complex obesity science. He has also developed simple, implementable behavioural therapy models for obesity care. Kalra frequently draws analogies between obesity management and concepts from quantum physics, traditional customs, and religious texts. Several of these ideas have been widely cited and discussed.
==== Iron recycling and loss ==== Most of the iron in the body is hoarded and recycled by the reticuloendothelial system, which breaks down aged red blood cells. In contrast to iron uptake and recycling, there is no physiologic regulatory mechanism for excreting iron. People lose a small but steady amount by gastrointestinal blood loss, sweating and by shedding cells of the skin and the mucosal lining of the gastrointestinal tract. The total amount of loss for healthy people in the developed world amounts to an estimated average of 1 mg a day for men, and 1.5–2 mg a day for women with regular menstrual periods. People with gastrointestinal parasitic infections, more commonly found in developing countries, often lose more. Those who cannot regulate absorption well enough get disorders of iron overload. In these diseases, the toxicity of iron starts overwhelming the body's ability to bind and store it.
Cysteine-rich proteins (CRP, cysteine-rich peptide or disulphide-rich peptide) are small proteins that contain a large number of cysteines. These cysteines either cross-link to form disulphide bonds, or bind metal ions by chelation, stabilising the protein's tertiary structure. CRPs include a highly conserved secretion peptide signal at the N-terminus and a cysteine-rich region at the C-terminus.
== See also == International FOP Association – American organization Osteogenesis imperfecta – Group of genetic disorders resulting in fragile bones, a condition characterized by bones breaking unusually easily, caused by mutations in genes related to those responsible for FOP Progressive osseous heteroplasia – Rare genetic condition characterised by cutaneous or subcutaneous ossification FOP Friends
Sources: en.wikipedia.org
=== Precambrian bodies === The Earth formed around 4.6 billion years ago, with unicellular life emerging somewhat later after the cessation of the Late Heavy Bombardment, a period of intense asteroid impacts possibly caused by migration of the gas giant planets to their current orbits, however multicellularity and bodies are a relatively recent event in Earth's history. Bodies first started appearing towards the end of the Precambrian Era, during the Ediacaran period. The fossils of the Ediacaran period were first found in Southern Australia in the Ediacara Hills, hence the name. However these fossils were initially thought to be part of the Cambrian and it wasn't until the late 1950s when Martin Glaessner identified the fossils as actually being from the Precambrian era. The fossils that were found date to about 600 million years ago and are found in a variety of morphologies.
The quadriplegia dissipates once the patient lies supine. An extremely rare complication of sCSFL is third nerve palsy, where the ability to move one's eyes becomes difficult and interrupted due to compression of the third cranial nerve. There are documented cases of reversible frontotemporal dementia and coma. Coma due to a CSF leak has been successfully treated by using blood patches and/or fibrin glue and placing the person in the Trendelenburg position. Empty sella syndrome, a bony structure that surround the pituitary gland, occurs in CSF leak patients.
Evocative/suppression testing refers to a class of tests performed where one substance is measured both before and after the administration of another substance to determine if the levels are stimulated ("evocative") or suppressed. They are most commonly performed in the evaluation of possible endocrine disorders. Certain tests are performed in the evaluation of multiple conditions, and not all listed substances may be measured in each test. Examples include:
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.